Critical appraisal of ranibizumab in the treatment of diabetic macular edema

References

• RosenfeldPJBrownDMHeierJSRanibizumab for age-related macular degenerationN Engl J Med20063551419143117021318
   PubMed Web of Science ®Google Scholar
• BrownDMKaiserPKMichelsMRanibizumab versus verteporfin for neovascular age-related macular degenerationN Engl J Med20063341432144417021319
   PubMed Web of Science ®Google Scholar
• Diabetic Retinopathy Clinical Research Network; ElmanMJBresslerNMQinHExpanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edemaOphthalmology201111860961421459214
   PubMedGoogle Scholar
• BrownDMCampochiaroPASinghRPCRUISE investigatorsRanibizumab for macular edema following central retinal vein occlusion. Six month primary end point results of a phase III studyOphthalmology20101171124113320381871
   PubMedGoogle Scholar
• BrownDMCampochiaroPABhisitfulRBSustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III studyOphthalmology20111181594160221684606
   PubMed Web of Science ®Google Scholar
• AielloLPAveryRIArriggPGVascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disordersN Engl J Med1994331148014877526212
   PubMed Web of Science ®Google Scholar
• FunatsuHYamashitaHIkedaTNakanishiYKitanoSHoriSAngiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with diabetic macular edema and other retinal disordersAm J Ophthalmol200213353754311931788
   PubMed Web of Science ®Google Scholar
• HeierJSBrownDMChongVIntravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degenerationOphthalmology20121192537254823084240
   PubMed Web of Science ®Google Scholar
• American Academy of Ophthalmology Retina/Vitreous PanelPreferred Practice Pattern Guidelines. Diabetic RetinopathySan Francisco, CAAmerican Academy of Ophthalmology20084 Available at: http://one.aao.org/CE/PracticeGuidelines/PPP.aspxAccessed April 9, 2012
   Google Scholar
• International Diabetes FederationIDF Diabetes Atlas4th edBrussels, BelgiumInternational Diabetes Federation Executive Office2009 Available from: http://www.diabetesatlas.org/Accessed April 20, 2011
   Google Scholar
• KingHAubertREHermanWHGlobal burden of diabetes, 1995–2025: prevalence, numerical estimates, and projectionsDiabetes Care199821141414319727886
   PubMed Web of Science ®Google Scholar
• NguyenQDShahSMHeierJSPrimary end point (six months) results of the ranibizumab for edema of the macula in diabetes (READ-2) studyOphthalmology20091162175218119700194
   PubMed Web of Science ®Google Scholar
• KleinRKleinBEMossSEThe Wisconsin Epidemiologic study of diabetic retinopathy. IV. Diabetic macular edemaOphthalmology198491146414746521986
   PubMed Web of Science ®Google Scholar
• KleinRKleinBEMossSEDavisMDDeMetsDLThe Wisconsin Epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 yearsArch Ophthalmol19841025205266367724
   PubMed Web of Science ®Google Scholar
• KleinRKleinBEMossSEDavisMDDeMetsDLThe Wisconsin Epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more yearsArch Ophthalmol19841025275326367725
   PubMed Web of Science ®Google Scholar
• The Diabetes Control and Complications Trial Research GroupThe effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitusN Engl J Med19933299779868366922
   PubMed Web of Science ®Google Scholar
• Photocoagulation for diabetic macular edemaEarly Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study Research GroupArch Ophthalmol1985103179618062866759
   PubMed Web of Science ®Google Scholar
• SchatzHMadeiraDMcDonaldHRJohnsonRNProgressive enlargement of laser scars following grid laser photocoagulation for diffuse diabetic macular edemaArch Ophthalmol1991109154915511755735
   PubMedGoogle Scholar
• StewartMWCorticosteroid use for diabetic macular edema: old fad or new trend?Curr Diab Rep20121236437522581206
   PubMed Web of Science ®Google Scholar
• MitchellPBandelloFSchmidt-ErfurthUThe RESTORE study. Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edemaOphthalmology201111861562521459215
   PubMed Web of Science ®Google Scholar
• NguyenQDBrownDMMarcusDMet al; on behalf of theRISERIDE Research GroupRanibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDEOphthalmology201211978980122330964
   PubMed Web of Science ®Google Scholar
• ArevaloJFSanchezJGWuLPrimary intravitreal bevacizumab for diffuse diabetic macular edema. The Pan-American Collaborative Retina Study Group at 24 monthsOphthalmology20091161488149719545900
   PubMed Web of Science ®Google Scholar
• MichaelidesMKainesAHamiltonRDA prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study)Ophthalmology20101171078108620416952
   PubMed Web of Science ®Google Scholar
• SultanMBZhouDLoftusJMacugen 1013 Study GroupA phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edemaOphthalmology20111181107111821529957
   PubMed Web of Science ®Google Scholar
• DoDVSchmidt-ErfurthUGonzalezVHThe DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edemaOphthalmology20111181819182621546089
   PubMed Web of Science ®Google Scholar
• BrownleeMBiochemistry and molecular cell biology of diabetic complicationsNature200141481382011742414
   PubMed Web of Science ®Google Scholar
• SemenzaGSignal transduction to hypoxia-inducible factor 1Biochem Pharmacol20026499399812213597
   PubMed Web of Science ®Google Scholar
• MaxwellPHRatcliffePJOxygen sensors and angiogenesisSemin Cell Dev Biol200213293711969369
   PubMed Web of Science ®Google Scholar
• VinoresSAYoussriAILunaJDUpregulation of vascular endothelial growth factor in ischemic and non-ischemic human and experimental retinal diseaseHistol Histopathol199712991099046048
   PubMed Web of Science ®Google Scholar
• CaldwellRBBartoliMBehzadianMAVascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectivesDiabetes Metab Res Rev20031944245514648803
   PubMed Web of Science ®Google Scholar
• EjazSChekarovaIEjazAImportance of pericytes and mechanisms of pericyte loss during diabetes retinopathyDiabetes Obes Metab200810536317941874
   PubMed Web of Science ®Google Scholar
• StewartMWThe expanding role of vascular endothelial growth factor inhibitors in ophthalmologyMayo Clin Proc201287778822212972
   PubMed Web of Science ®Google Scholar
• LuMPerezVLMaNVEGF increases retinal vascular ICAM-1 expression in vivoInvest Ophthalmol Vis Sci1999401808181210393052
   PubMed Web of Science ®Google Scholar
• BarleonBSozzaniSZhouDMigration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1Blood199687333633438605350
   PubMed Web of Science ®Google Scholar
• MiyamotoKKhosrofSBursellPrevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibitionProc Natl Acad Sci USA199996108361084110485912
   PubMed Web of Science ®Google Scholar
• JoussenAMMurataTTsujikawaALeukocyte-mediated endothelial cell injury and death in the diabetic retinaAm J Pathol200115814715211141487
   PubMed Web of Science ®Google Scholar
• MichaelsonICThe mode of development of the vascular system of the retina with some observations on its significance for certain retinal disordersTrans Ophthalmol Soc UK19486816251710
   Google Scholar
• SengerDRGalliSJDvorakAMPerruzziCAHarveyVSDvorakHFTumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluidScience1983129839856823562
   PubMed Web of Science ®Google Scholar
• FerraraNHenzelWJPituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cellsBiochem Biophys Res Commun19891618518582735925
   PubMed Web of Science ®Google Scholar
• ConnollyDTHeuvelmanDMNelsonRTumor vascular permeability factor stimulates endothelial cell growth and angiogenesisJ Clin Invest198984147014782478587
   PubMed Web of Science ®Google Scholar
• StewartMWAflibercept (VEGF-TRAP): the next anti-VEGF drugInflamm Allergy Drug Targets20111049750821999177
   PubMedGoogle Scholar
• FerraraNGerberH-PLeCouterJThe biology of VEGF and its receptorsNat Med2003966967612778165
   PubMed Web of Science ®Google Scholar
• GerberHPMcMurtreyAKowalskiJVascular endothelial growth factor regulates endothelial cell survival through the phosphotidylinositol 3’-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activationJ Biol Chem199827330336303439804796
   PubMed Web of Science ®Google Scholar
• FerraraNHillanKJGerberH-PNovotnyWDiscovery and development of bevacizumab, an anti-VEGF antibody for treating cancerNat Rev Drug Discov2004339140015136787
   PubMed Web of Science ®Google Scholar
• FerraraNDamicoLShamsNLowmanHKimRDevelopment of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degenerationRetina20062685987017031284
   PubMed Web of Science ®Google Scholar
• PapadopoulosNMartinJRuanQBinding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumabAngiogenesis20121517118522302382
   PubMed Web of Science ®Google Scholar
• BakriSJSnyderMRReidJMPulidoJSEzzatMKSinghRJPharmacokinetics of intravitreal ranibizumab (Lucentis)Ophthalmology20071142179218218054637
   PubMed Web of Science ®Google Scholar
• ChristofordisJBCarltonMMKnoppMVHinkleGHPet/CT imaging of I-124-radiolabeled bevacizumab and ranibizumab after intravitreal injection in a rabbit modelInvest Ophthalmol Vis Sci2011525899590321685343
   PubMed Web of Science ®Google Scholar
• MordentiJCuthbertsonRAFerraraNComparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administrationToxicol Pathol19992753654410528633
   PubMed Web of Science ®Google Scholar
• GaudreaultJFeiDRusitJSubocPShiuVPreclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administrationInvest Ophthalmol Vis Sci20054672673315671306
   PubMed Web of Science ®Google Scholar
• KrohneTULiuZHolzFGMeyerCHIntraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humansAm J Ophthalmol201215468268622818800
   PubMed Web of Science ®Google Scholar
• MeyerCHKrohneTUHolzFGIntraocular pharmacokinetics after a single intravitreal injection of 1.5 mg versus 3.0 mg of bevacizumab in humansRetina2011311877188421738089
   PubMed Web of Science ®Google Scholar
• XuLLuTTuomiLPharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approachInvest Ophthalmol Vis Sci2013541616162423361508
   PubMed Web of Science ®Google Scholar
• ChakravarthyUHardingSPRogersCARanibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trialOphthalmology20121191399141122578446
   PubMedGoogle Scholar
• RegilloCDBrownDMAbrahamPRandomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1Am J Ophthalmol200814523924818222192
   PubMed Web of Science ®Google Scholar
• Schmidt-ErfurthUEldemBGuymerREXCITE Study GroupEfficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE studyOphthalmology201111883183921146229
   PubMed Web of Science ®Google Scholar
• GilbertREVranesDBerkaJLVascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate modelAm J Pathol1998145574584
   Google Scholar
• RobertsWGPaladeGEIncreased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factorJ Cell Sci1995108236923797673356
   PubMed Web of Science ®Google Scholar
• QaumTXuQJoussenAMVEGF-initiated blood-retinal barrier breakdown in early diabetesInvest Ophthalmol Vis Sci2001422408241311527957
   PubMed Web of Science ®Google Scholar
• TolentinoMJMcLeodDSTaomotoMOtsujiTAdamisAPLuttyGAPathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primateAm J Ophthalmol200213337338511860975
   PubMed Web of Science ®Google Scholar
• FunatsuHYamashitaHNomaHMimuraTYamashitaTHoriSIncreased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edemaAm J Ophthalmol2002133707711755841
   PubMed Web of Science ®Google Scholar
• FunatsuHYamashitaHIkedaTMimuraTEguchiSHoriSVitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edemaOphthalmology20031101690169613129863
   PubMed Web of Science ®Google Scholar
• CampochiaroPAChoyDFDoDVMonitoring ocular drug therapy by analysis of aqueous samplesOphthalmology20091162158216419700195
   PubMed Web of Science ®Google Scholar
• NguyenQDShahSMVan AndenESungJUVitaleSCampochiaroPASupplemental oxygen improves diabetic macular edema: a pilot studyInvest Ophthalmol Vis Sci20044561762414744906
   PubMed Web of Science ®Google Scholar
• Macugen Diabetic Retinopathy Study GroupA phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edemaOphthalmology20051121747175716154196
   PubMed Web of Science ®Google Scholar
• NguyenQDTatlipinarSShahSMVascular endothelial growth factor is critical stimulus for diabetic macular edemaAm J Ophthalmol200614296196917046701
   PubMed Web of Science ®Google Scholar
• ChunDWHeierJSToppingTMDukerJSBankertJMA pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edemaOphthalmology20061131706171217011952
   PubMed Web of Science ®Google Scholar
• NguyenQDShahSMKhwajaAATwo-year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) studyOphthalmology20101172146215120855114
   PubMed Web of Science ®Google Scholar
• DoDVNguyenQDKhwajaAAREAD-2 Study GroupRanibizumab for edema of the macula in diabetes study; 3-year outcomes and the need for prolonged frequent treatmentJAMA Ophthalmol201313113914523544200
   PubMed Web of Science ®Google Scholar
• BusbeeBGHoACBrownDMHARBOR Study GroupTwelve-month efficacy and safety of 0.5 mg or 2 mg ranibizumab in patients with subfoveal neovascular age-related macular degenerationOphthalmology1232013 [Epub ahead of print.]
   Google Scholar
• DoDVCampochiaroPABoyerDSRead 3 Research GroupSix-month and one-year interim results of the READ 3 study: ranibizumab for edema of the macula in diabetesAbstract presented at the 2012 annual meeting of the Association for Research in Vision and OphthalmologyMay 6–9, 2012Fort Lauderdale, FL
   Google Scholar
• MassinPBandelloFGarwegJGSafety and efficacy of ranibizumab in diabetic macular edema (RESOLVE study): a 12-month, randomized, controlled, double-masked, multicenter phase II studyDiabetes Care2010332399240520980427
   PubMed Web of Science ®Google Scholar
• Diabetic Retinopathy Clinical Research Network; ElmanMJAielloLPBeckRWRandomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edemaOphthalmology20101171064107720427088
   PubMedGoogle Scholar
• ManousaridisKTalksJMacular ischaemia: a contraindication for anti-VEGF treatment in retinal vascular disease?Br J Ophthalmol20129617918422250209
   PubMedGoogle Scholar
• SoheilianMRamezaniAObudiARandomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edemaOphthalmology20091161142115019376585
   PubMed Web of Science ®Google Scholar
• Diabetic Retinopathy Clinical Research NetworkA phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edemaOphthalmology20071141860186717698196
   PubMed Web of Science ®Google Scholar
• SolaimanKADiabMMAbo-EleninMIntravitreal bevacizumab and/or macular photocoagulation as a primary treatment for diffuse diabetic macular edemaRetina2011301638164520838357
   PubMedGoogle Scholar
• LamDSLaiTYLeeVYEfficacy of 1.25 mg versus 2.5 mg intravitreal bevacizumab for diabetic macular edema: six-month results of a randomized controlled trialRetina20092929229919287286
   PubMed Web of Science ®Google Scholar
• Clinicaltrials.govDiabetic Retinopathy Clinical Research NetworkComparative effectiveness study of intravitreal aflibercept, bevacizumab, and ranibizumab for DME ClinicalTrial.gov Identifier NCT01627249. Available from: clinicaltrials.gov/ct2/show/NCT01627249Accessed October 15, 2012
   Google Scholar
• BrownDMMichelsMKaiserPKANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR StudyOphthalmology2009116576519118696
   PubMed Web of Science ®Google Scholar
• Schmidt-ErfurthUClinical safety of ranibizumab in age-related macular degenerationExpert Opin Drug Saf2010914916520001757
   PubMed Web of Science ®Google Scholar
• SmiddyWEEconomic considerations of macular edema therapiesOphthalmology20111181827183321507488
   PubMed Web of Science ®Google Scholar